In acute myeloid leukemia (AML), RIPK3 signaling might be epigenetically repressed in leukemic cells isolated from a subgroup of AML patients such as AML with RUNX1-ETO or FLT3-ITD mutations (Hockendorf et al., 2016). Here, RUNX1 is linked to acute myeloid leukemia.